5243482025-04-012025-06-305243482025-04-012025-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares524348AARTIDRUGSNOTLISTEDINE767A01016AARTI DRUGS LIMITEDMain BoardEquity2025-04-012026-03-312025-07-182025-07-15INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-1812:00:002025-07-1816:20:00Not applicablefalsefalseThe disclosure for the defualt on Loans and Debt Securities is not applicable to the Company as there is no defualt. <BR> 2025-04-012025-06-30AuditedStandalone5209600000380000052134000003338100000112100000-12650000023290000068200000122700000101340000047609000004525000000452500000-5390000020000000-33900000048640000000004864000000486400000912700000105.335.33005.335.331. The above results for the Quarter ended 30th June, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 18th July, 2025. <BR> <BR> 2.The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. <BR> <BR> 3.A s on June 30, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. <BR> <BR> 4.Company has only one business segment i.e. pharmaceuticals. <BR> <BR> 5. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. <BR> <BR> 6. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. <BR> <BR> For AARTI DRUGS LIMITED <BR> <BR> Rashesh C. Gogri <BR> ( Managing Director ) <BR> DIN: 00066291 <BR> <BR> Place: Mumbai <BR> Date: 18th July' 2025Other Expenses1013400000